(Boursier.com) — Equasens rose modestly by 0.8% this Friday to 70.80 euros, while the Group recorded an increase in its turnover as of June 30, 2022 of 10.30% to 103.57 ME compared to the 1st half of 2021. On a like-for-like basis, turnover increased by 7.68% to €101.11 million, which confirms the merits of the acquisition of PROKOV EDITIONS carried out in Q4 2021.
(+18.92%) and the Net Income Group Share at 19.73 ME (+18.96%). As of June 30, Basic Earnings per Share amounted to 1.31 euro compared to 1.10 euro as of June 30, 2021 (+19.10%).
Equasens’ available gross cash position as of June 30 was up to €121.74 million compared to €107.87 million as of December 31, 2021. With net cash (net of all borrowings) of €45.45 million, the group retains strong autonomy and significant investment capacity for external growth operations. Equity, Group share, as of June 30, 2022 amounted to €161.78 million.
Outlook for the 2nd half of 2022
Equasens continues to stand out with recent certifications Segur of its software offers – regularly, the first among all market players – and consolidates its positioning as a structuring player and leader in the world of Health.
The group is confident and confirms its growth and profitability ambitions for 2022, given the non-recurring nature of the costs recorded in the 1st half… Portzamparc speaks of a “solid” first half, which represents rather a good transition point compared to our annual scenario, knowing that we are still counting on an acceleration of organic growth in H2 (PZP +11.8%)”. The analyst remains buying, aiming for a price of 104 euros. For its part, GreenSome Finance cut its target from 103.1 to 87.33 euros, while remaining on the buy side.
©2022 Boursier.com